The Impact of Methylprednisolone Pulses during Relapses of Multiple Sclerosis on the Kinetics of Anti-Interferon-Beta Antibodies

被引：0
作者：
Giantzi, Virginia [1 ]
Karapanayiotides, Theodoros [1 ]
Lagoudaki, Roza [1 ,2 ]
Poulatsidou, Kyriaki-Nefeli [1 ,2 ]
Lourbopoulos, Athanasios [1 ,2 ]
Daniilidis, Michail [1 ,2 ]
Taskos, Nikolaos [1 ]
Milonas, Loannis [1 ]
Grigoriadis, Nikolaos [1 ,2 ]
机构：
[1] Aristotle Univ Thessaloniki, AHEPA Univ Hosp, Dept Neurol 2, GR-54006 Thessaloniki, Greece
[2] Aristotle Univ Thessaloniki, AHEPA Univ Hosp, Lab Expt Neurol & Neuroimmunol, GR-54006 Thessaloniki, Greece
来源：
EUROPEAN NEUROLOGY | 2016年 / 75卷 / 1-2期
关键词：
Neutralizing antibodies; Binding antibodies; Anti-interferon-beta antibodies; Multiple sclerosis; NEUTRALIZING ANTIBODIES; IFN-BETA; DIAGNOSTIC-CRITERIA; BINDING-ANTIBODIES; MS; CORTICOSTEROIDS; IFN-BETA-1B; THERAPY; TRIAL;
D O I：
10.1159/000444319
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Background/Aims: We assessed the, hitherto unknown, impact of intravenous methylprednisolone (ivMP) pulses during relapses of multiple sclerosis (MS) on the kinetics of anti-interferon-beta neutralizing antibodies (Nabs) and binding antibodies (Babs). Methods: Babs (ELISA) and Nabs (antiviral cytopathic effect assay) titers were evaluated before, immediately after and at 1 month following ivMP in 60 MS patients. Results: ivMP reduces Nabs and Babs titers for at least 1 month. Baseline titers determine Nabs and Babs seronegativity at the end of ivMP. Clinical response to ivMP tends to be better in Nabs(+) patients. Conclusion: Sampling for Nabs/Babs should be avoided during or shortly after ivMP to avoid transient positive or negative results that may obscure the decision to switch treatment. (C) 2016 S. Karger AG, Basel
引用
收藏
页码：82 / 88
页数：7
相关论文
共 50 条
[21]   NEUTRALIZING ANTIBODIES AGAINST INTERFERON-BETA IN BULGARIAN ADOLESCENT MULTIPLE SCLEROSIS PATIENTS [J].
Ivanova, Sonya ;
Skrobanska, Raliza ;
Kolyovska, Vera ;
Milanov, Ivan ;
Dimitrova, Valentina ;
Bojinova, Veneta .
COMPTES RENDUS DE L ACADEMIE BULGARE DES SCIENCES, 2018, 71 (09) :1265-1271
[22]   The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis [J].
Koch-Henriksen, N. ;
Sorensen, P. S. ;
Bendtzen, K. ;
Flachs, E. M. .
MULTIPLE SCLEROSIS, 2009, 15 (05) :601-605
[23]   Neutralizing Antibodies Are Associated with a Reduction of Interferon-β Efficacy during the Treatment of Japanese Multiple Sclerosis Patients [J].
Sato, Douglas Kazutoshi ;
Nakashima, Ichiro ;
Fukazawa, Toshiyuki ;
Shimizu, Yuko ;
Tomizawa, Yuji ;
Yokoyama, Kazumasa ;
Misu, Tatsuro ;
Creeke, Paul I. ;
Farrell, Rachel ;
Giovannoni, Gavin ;
Itoyama, Yasuto ;
Fujihara, Kazuo ;
Aoki, Masashi .
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2012, 228 (02) :85-92
[24]   Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies [J].
Scagnolari, Carolina ;
Duda, Petra ;
Bagnato, Francesca ;
De Vito, Gabriella ;
Alberelli, Alessia ;
Lavolpe, Vito ;
Girardi, Enrico ;
Durastanti, Valentina ;
Trojano, Maria ;
Kappos, Ludwig ;
Antonelli, Guido .
JOURNAL OF NEUROLOGY, 2007, 254 (05) :597-604
[25]   Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies [J].
Carolina Scagnolari ;
Petra Duda ;
Francesca Bagnato ;
Gabriella De Vito ;
Alessia Alberelli ;
Vito Lavolpe ;
Enrico Girardi ;
Valentina Durastanti ;
Maria Trojano ;
Ludwig Kappos ;
Guido Antonelli .
Journal of Neurology, 2007, 254 :597-604
[26]   Neutralizing Antibodies Against Interferon-Beta in Korean Patients with Multiple Sclerosis [J].
Hyun, Jae-Won ;
Kim, Gayoung ;
Kim, Yeseul ;
Kong, Byungsoo ;
Joung, Aeran ;
Park, Na Young ;
Jang, Hyunmin ;
Shin, Hyun-June ;
Kim, Su-Hyun ;
Ahn, Suk-Won ;
Shin, Ha Young ;
Huh, So-Young ;
Kim, Woojun ;
Park, Min Su ;
Kim, Byung-Jo ;
Kim, Byoung Joon ;
Oh, Jeeyoung ;
Kim, Ho Jin .
JOURNAL OF CLINICAL NEUROLOGY, 2018, 14 (02) :186-190
[27]   Neutralizing antibodies to interferon beta: implications for the management of multiple sclerosis [J].
Bertolotto, A .
CURRENT OPINION IN NEUROLOGY, 2004, 17 (03) :241-246
[28]   Cross-reactivity of antibodies against interferon beta in multiple sclerosis patients and interference of the JAK-STAT signaling pathway [J].
Hurtado-Guerrero, Isaac ;
Jesus Pinto-Medel, Maria ;
Urbaneja, Patricia ;
Luis Rodriguez-Bada, Jose ;
Ortega-Pinazo, Jesus ;
Serrano, Pedro ;
Fernandez, Oscar ;
Leyva, Laura ;
Oliver-Martos, Begona .
SCIENTIFIC REPORTS, 2017, 7
[29]   Psoriasis during interferon beta treatment for multiple sclerosis [J].
La Mantia, Loredana ;
Capsoni, F. .
NEUROLOGICAL SCIENCES, 2010, 31 (03) :337-339
[30]   Malignant melanoma in a multiple sclerosis patient with persistent neutralizing antibodies to interferon-beta [J].
Gibbs, E. ;
Tremlett, H. ;
Ball, N. ;
Hashimoto, S. .
EUROPEAN JOURNAL OF NEUROLOGY, 2008, 15 (01) :E4-E4
12345